Collaboration Opportunities for Industry
DSF has the tools, experience, and community connections you need to accelerate your Dravet syndrome treatment development program. Our established resources facilitate each phase of development. Join us in working togther to address the many unmet needs for treatment of Dravet syndrome.
Contact us to connect and learn more.
Why Dravet syndrome?
Dravet syndrome is a rare developmental and epileptic encephalopathy that affects 1 in every 15,700 children worldwide, with the majority of patients carrying a mutation in the sodium channel gene SCN1A. It begins in infancy and proceeds with accumulating morbidity that significantly impacts individuals throughout their lifetime, increasing in severity in early childhood. Â
Current treatment options are limited, and the constant care required for someone suffering from Dravet syndrome can severely impact the quality of life for patients and families. Patients with Dravet syndrome face a 15-20% mortality rate due to SUDEP (Sudden Unexpected Death in Epilepsy), prolonged seizures, seizure-related accidents such as drowning, and infections.
Why Now?
We believe that life-changing treatments are on the horizon because Dravet syndrome has:
- An Identified Causal Gene
- A Predictive Mouse Model
- Established Centers of Excellence
- Clinical Endpoints in Development
- An Educated and Engaged Patient Community
Our Resources
DSF is the largest nongovernmental researcher funder for Dravet syndrome, worldwide. We act as a convener, connecting patient families, clinicians, researchers, and biopharma. Our resources include:
- Network of Dravet syndrome patient families
- Scientific Advisory Board
- Medical Advisory Board
- Academic Research Funding
- Commercial iPSC cell line
- 21 US-based Comprehensive Care Centers
- Clinical Trials & Pipeline Webpage
Why DSF?
As the leading Dravet syndrome research and advocacy organization, the Dravet Syndrome Foundation (DSF) has invested over $6.7M in researcher, leading to….
Â
Companies we have worked with: